Microdissection-based mutational genotyping of serous borderline tumors of the ovary

International Journal of Gynecological Pathology

Volumn 24, Issue 1, 2005, Pages 56-61

  Krishnamurti, Uma ^a   Sasatomi, Eizaburo ^a,b   Swalsky, Patricia A ^c   Jones, Mirka W ^a,b   Finkelstein, Sydney D ^d  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Redpath Integrated Pathology ^*  (United States)

^d RedPath Integrated Pathology   (United States)

Author keywords

Clonality; Loss of heterozygosity; Ovary; Serous borderline tumor

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 1P; CHROMOSOME 5Q; CHROMOSOME 9P; CHROMOSOME 9Q; CHROMOSOME ANALYSIS; CHROMOSOME MARKER; CLONAL VARIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE LOSS; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MICRODISSECTION; MICROSATELLITE MARKER; MUTATIONAL ANALYSIS; OVARY TUMOR; PRIORITY JOURNAL; SEROUS BORDERLINE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MICRODISSECTION; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 11244351620     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000148339.62017.d8     Document Type: Article

References (34)

1. Gardner GJ, Birrer MJ. Ovarian tumors of low malignant potential: Can molecular biology solve this enigma? J Natl Cancer Inst 2001; 93:2-3.
2. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, ed. Blaustein's Pathology of the female genital tract. 5th ed. New York: Springer-Verlag, 2002:791-905.
3. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31:539-57.
4. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types: A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996;20: 1331-45.
5. Bell KA, Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 2001;25:419-32.
6. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53: 3103-8.
7. Singer G, Oldt R 3rd, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003;95:484-6.
8. Singer G, Shih Ie M, Truskinovsky A, et al. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003;22:37-41.
9. Wertheim I, Muto MG, Welch WR, et al. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994; 86:1549-51.
10. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164:1511-8.
11. Saretzki G, Hoffmann U, Rohlke P, et al. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997;80:1241-9.
12. Diebold J, Seemuller F, Lohrs U. K-ras mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest 2003;83:251-8.
13. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001;93:1147-52.
14. Lu KH, Bell DA, Welch WR, et al. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998;58:2328-30.
15. Sieben NL, Kolkman-Uljee SM, Flanagan AM, et al. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am J Pathol 2003;162:1095-101.
16. Sherman ME, Berman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol 2004;35:961-70.
17. Cong WM, Bakker A, Swalsky PA, et al. Multiple genetic alterations involved in the tumorigenesis of human cholangiocarcinoma: A molecular genetic and clinicopathological study. J Cancer Res Clin Oncol 2001;127:187-92.
18. Gallion HH, Powell DE, Morrow JK, et al. Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 1992;47:137-42.
19. Dodson MK, Hartmann LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 1993;53:4456-60.
20. Cooke IE, Shelling AN, Le Meuth VG, et al. Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer 1996;15:223-33.
21. Aguiari G, Martinello R, Casaro D, et al. LOH of chromosome 6q compared with LOH of 17q and 18q in ovarian cancers: Relationship to p53 expression and clinicopathological findings. Int J Gynecol Cancer 1999;9:147-55.
22. Garcia A, Bussaglia E, Machin P, et al. Loss of heterozygosity on chromosome 17q in epithelial ovarian tumors: Association with carcinomas with serous differentiation. Int J Gynecol Pathol 2000;19: 152-7.
23. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999;96:214-9.
24. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
25. Gershenson DM, Deavers M, Diaz S, et al. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 1999;5:4053-8.
26. Kupryjanczyk J, Bell DA, Dimeo D, et al. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26: 387-92.
27. Lee JH, Kang YS, Park SY, et al. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:43-50.
28. Zanotti KM, Hart WR, Kennedy AW, et al. Allelic imbalance on chromosome 17p13 in borderline (low malignant potential) epithelial ovarian tumors. Int J Gynecol Pathol 1999;18:247-53.
29. Zheng J, Benedict WF, Xu HJ, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst 1995;87:1146-53.
30. Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002;16:499-512.
31. Slomovitz BM, Caputo TA, Gretz HF III, et al. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol 2002;26:592-600.
32. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
33. Staebler A, Heselmeyer-Haddad K, Bell K, et al. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 2002;33:47-59.
34. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-7.